Highlights and Quick Summary
Current EV/EBITDA of AbbVie Inc. is 14.37 (as of December 30, 2020)
- EV/EBITDA for the quarter ending December 30, 2020 was 14.37 (a 1.16% increase compared to previous quarter)
- Year-over-year quarterly EV/EBITDA increased by 62.03%
- Annual EV/EBITDA for 2020 was 14.37 (a 36.44% increase from previous year)
- Annual EV/EBITDA for 2019 was 10.53 (a -50.78% decrease from previous year)
- Annual EV/EBITDA for 2018 was 21.39 (a 27.98% increase from previous year)
Visit stockrow.com/ABBV
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical EV/EBITDA of AbbVie Inc.
Most recent EV/EBITDAof ABBV including historical data for past 10 years.Interactive Chart of EV/EBITDA of AbbVie Inc.
AbbVie Inc. EV/EBITDA for the past 10 Years (both Annual and Quarterly)
Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
---|---|---|---|---|---|
2020 | 14.37 | 14.2 | 17.3 | 8.87 | 14.37 |
2019 | 10.53 | 16.39 | 15.59 | 18.22 | 10.53 |
2018 | 21.39 | 14.25 | 15.23 | 14.93 | 21.39 |
2017 | 16.72 | 14.96 | 13.09 | 12.52 | 16.72 |
2016 | 12.5 | 12.89 | 13.43 | 12.74 | 12.5 |
2015 | 14.28 | 19.52 | 27.34 | 22.42 | 14.28 |
2014 | 26.44 | 15.7 | 14.3 | 13.27 | 26.44 |
2013 | 13.53 | 10.97 | 10.05 | 10.12 | 13.53 |
2012 | 9.05 | 9.05 | 9.05 | 9.05 | 9.05 |
2011 | 9.05 | 9.05 | 9.05 | 9.05 | 9.05 |
2010 | – | – | – | – | 9.05 |
Business Profile of AbbVie Inc.
Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.